$AEZS News
Last published 3mo ago
- 3mo agoAEZSApproval of Macrilen, Nda #205598 (Efficacy)FDA Approved DrugsApproval Date: 07/23/2026; Drug Name: Macrilen, Nda #205598; Active Ingredients: MACIMORELIN ACETATE; Company: Aeterna Zentaris; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 205598
- 2y agoAEZSAeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.GlobeNewswireTORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ:AEZS) (TSX:AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company
- 2y agoAEZSAeterna Zentaris Announces Results of Virtual 2024 Meeting of ShareholdersGlobeNewswireTORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a
- 2y agoAEZSAeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyGlobeNewswireCompany expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a
- 2y agoAEZSCRPOFAeterna Zentaris and Ceapro Complete Merger TransactionGlobeNewswireTORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company") and Ceapro Inc. (TSXV:CZO) (OTCQX:CRPOF) ("Ceapro"), two innovative biopharmaceutical
- 2y agoAEZSAeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption DateGlobeNewswireTORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified
- 2y agoAEZSAeterna Zentaris Announces Details Regarding Transaction with CeaproGlobeNewswireTORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company") announces that it has finalized certain details regarding the previously announced merger of
- 2y agoAEZSAeterna Zentaris Reports First Quarter 2024 Financial ResultsGlobeNewswireCompany ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of
- 2y agoAEZSAeterna Zentaris Announces Effective Date of Share ConsolidationGlobeNewswireTORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company") announces that it has filed articles of amendment to effect the previously announced share
- 2y agoAEZSCRPOFCeapro Receives Final Court Approval for Merger with Aeterna ZentarisGlobeNewswireTORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro") are pleased to announce that the
- 2y agoAEZSAeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyGlobeNewswire- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock
- 2y agoAEZSCRPOFAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsGlobeNewswireTORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro") are pleased to announce that securityholders of
- 2y agoAEZSCRPOFLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyGlobeNewswireISS states in its Aeterna Zentaris FOR recommendation that "on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear
- 2y agoAEZSCRPOFAeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with CeaproGlobeNewswireAeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available at
- 2y agoAEZSCRPOFAeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical CompanyGlobeNewswireTORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro Inc. (TSXV:CZO) (OTCQX:CRPOF) ("Ceapro"), two innovative biopharmaceutical development
- 3y agoAEZSAeterna Zentaris Reports Third Quarter 2023 Financial ResultsGlobeNewswire- Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to fund
- 3y agoAEZSAeterna Zentaris to Participate at the Virtual Investor Ask the CEO ConferenceGlobeNewswire– Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc.
- 3y agoAEZSAeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireTORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified
- 3y agoAEZSAeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate UpdateGlobeNewswireHighlights progress, recent developments and upcoming key milestonesCompany continues to build growing body of data across pipeline, advancing towards first in human studiesStrong financial position with cash projected
- 3y agoAEZSAeterna Zentaris to Participate in the Virtual Investor Summer Spotlight SeriesGlobeNewswireLive moderated video webcast on Thursday, July 13th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty
- 3y agoAEZSAeterna Zentaris Announces Results of Virtual 2023 Meeting of ShareholdersGlobeNewswireTORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a
- 3y agoAEZSAeterna Zentaris Announces Virtual 2023 Meeting of ShareholdersGlobeNewswireTORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified
- 3y agoAEZSAeterna Zentaris Reports First Quarter 2023 Financial ResultsGlobeNewswire– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and commercialization
- 3y agoAEZSAeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT TrialGlobeNewswireU.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and
- 3y agoAEZSAeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswire– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing body of data across
- 3y agoAEZSPharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)GlobeNewswirePharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris' existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc.
- 3y agoAEZSAeterna Zentaris Provides Business Update and Outlines Key Upcoming MilestonesGlobeNewswireAeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across its development
- 3y agoAEZSAeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch EventGlobeNewswireLive video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty
- 4y agoAEZSAeterna Zentaris Reports Third Quarter 2022 Financial ResultsGlobeNewswire– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) --
- 4y agoAEZSAeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo NordiskGlobeNewswire– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal Phase 3 study "DETECT-trial" of macimorelin for the
- 4y agoAEZSAeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent HighlightsGlobeNewswire– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX
- 4y agoAEZSAeterna Zentaris Announces Effective Date of Share ConsolidationGlobeNewswireTORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the
- 4y agoAEZSAeterna Zentaris Announces Shareholder Approval of Share ConsolidationGlobeNewswireTORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnost
- 4y agoAEZSAeterna Zentaris Announces Further Adjournment of Shareholder MeetingGlobeNewswireTORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnost
- 4y agoAEZSAeterna Zentaris Announces Results of Annual Meeting of ShareholdersGlobeNewswire- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and com
- 4y agoAEZSAeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals ProgramGlobeNewswire– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th International Congress on Autoimmunity being he
- 4y agoAEZSAeterna Zentaris to Present at the JMP Securities Life Sciences ConferenceGlobeNewswireLive video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercia
- 4y agoAEZSAeterna Zentaris' Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone DeficiencyGlobeNewswireTORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnosti
- 4y agoAEZSAeterna Zentaris to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireTORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnosti
- 4y agoAEZSAeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share ConsolidationGlobeNewswireTORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that its
- 4y agoAEZSUpdate on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's DiseaseGlobeNewswire– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying ("AIM") Biologicals as a potential therapeutic treatment option for Parkinson's
- 4y agoAEZSAeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business OutlookGlobeNewswire– Continued advancement across diversified development pipeline – Company ended the quarter with $63.6 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, May 11, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (N
- 4y agoAEZSAeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of ImmunologistsGlobeNewswire– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson's Disease ("PD"), a neurodegenerative movement disorder TORONTO, ONTARIO, April 25, 2022 (GLOBE NEWSWIRE)
- 4y agoAEZSAeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in AdultsGlobeNewswire– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO, April 19, 2022 (GLOBE NEWSWIRE) -- Aeterna Zent
- 4y agoAEZSARECCNSPJTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: ARECACCESS Newswire- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the contin
- 4y agoAEZSAeterna Zentaris to Participate at the Virtual Investor 2022 CEO SpotlightGlobeNewswire– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET TORONTO, ONTARIO, April 12, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ
- 4y agoAEZSAeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on AutoimmunityGlobeNewswire– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need TORONTO, ONTARIO, April 11, 2022 (GLOBE NEWSWIRE
- 4y agoAEZSAeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business OutlookGlobeNewswire– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, March 29, 2022 (GLOBE NEWSWI
- 4y agoAEZSAeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyGlobeNewswire– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient enrollment expected to continue into 2023 TOR
- 4y agoAEZSAeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine ProgramsGlobeNewswire– Research agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis TORONTO, ONTARIO, March 10, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or th